Great success for New Modalities Nordic Investor Forum

Great success for The New Modalities Nordic Investor Forum 2025 that took place at GoCo Health Innovation City in Göteborg!

The day was filled with conversations and valuable insights shared from a fantastic lineup of panelists, keynotes, ecosystem actors, startups and investors.

The Investor Forum was an invite-only gathering where leading investors, pioneering companies, and academic visionaries meet to accelerate the next era of medicine – with a strong focus on new modalities and advanced therapies✨ New Modality Support (NMS) – coordinated by GU Ventures in collaboration with CCRM Nordic, OligoNova Hub, the Sahlgrenska Academy at University of Gothenburg, and Sahlgrenska University Hospital– is organizing the forum together with the national platform SciLifeLab Drug Discovery & Development (DDD).

We are proud to be joined by partners and participants from across the ecosystem, including AstraZeneca, CCRM Nordic, Hadean Ventures, Industrifonden, Innovestor Life Science, Johnson & Johnson, Life Science Invest, Oslo Cancer Cluster, Ribocure Pharmaceuticals AB, Sahlgrenska akademin, Skånes universitetssjukhus (Skåne University Hospital), and Vinnova.

A heartfelt thank you to all partners, companies, investors, and attendees – and to our generous sponsors Potter Clarkson and GoCo Health Innovation City – for making this forum possible. Together we’re building the future of therapies

About SciLifeLab DDD

The SciLifeLab Drug Discovery and Development (DDD) platform offers integrated drug discovery efforts to the Swedish academic research community. SciLifeLab DDD offer industry-standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept within small molecules, human antibodies, and new modality therapeutics.

For more information, please visit: https://www.scilifelab.se/units/ddd-platform/

About New Modality Support (NMS)

NMS supports the further development and commercialization of individual research projects, primarily within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. NMS is coordinated by GU Ventures and its partners are CCRM Nordic, OligoNova, Sahlgrenska Academy at the University of Gothenburg, and the Sahlgrenska University Hospital.

NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project ́s success.

For more information, please visit: https://newmodalitysupport.se